EZZ Life Science Holdings Ltd
EZZ Life Science Holdings Limited engages in formulation, production, marketing, and sale of the health and wellbeing products in Australia, New Zealand, Mainland China, and South-East Asia. The company operates through two segments, Brought in Lines and Company Owned Products. It is involved in the wholesale distribution of the EAORON branded skin care products to retailers; and direct-to-consum… Read more
EZZ Life Science Holdings Ltd (EZZ) - Total Liabilities
Latest total liabilities as of December 2025: AU$4.80 Million AUD
Based on the latest financial reports, EZZ Life Science Holdings Ltd (EZZ) has total liabilities worth AU$4.80 Million AUD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
EZZ Life Science Holdings Ltd - Total Liabilities Trend (2017–2024)
This chart illustrates how EZZ Life Science Holdings Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
EZZ Life Science Holdings Ltd Competitors by Total Liabilities
The table below lists competitors of EZZ Life Science Holdings Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ntaw Holdings Ltd
AU:NTD
|
Australia | AU$240.37 Million |
|
Cavitation Techs Inc
OTCQB:CVAT
|
USA | $249.00K |
|
Refinaria de Petróleos de Manguinhos S.A
SA:RPMG3
|
Brazil | R$17.72 Billion |
|
Aprogen Healthcare & Games Inc
KQ:109960
|
Korea | ₩15.37 Billion |
|
NAXS Nordic Access Buyout Fund AB
ST:NAXS
|
Sweden | Skr10.07 Million |
|
Sundaram Brake Linings Limited
NSE:SUNDRMBRAK
|
India | ₹1.05 Billion |
|
Bank Cimb Niaga Tbk
JK:BNGA
|
Indonesia | Rp313.14 Trillion |
Liability Composition Analysis (2017–2024)
This chart breaks down EZZ Life Science Holdings Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.57 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how EZZ Life Science Holdings Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for EZZ Life Science Holdings Ltd (2017–2024)
The table below shows the annual total liabilities of EZZ Life Science Holdings Ltd from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | AU$5.87 Million | +38.83% |
| 2023-12-31 | AU$4.23 Million | +38.28% |
| 2022-12-31 | AU$3.06 Million | +6.27% |
| 2021-12-31 | AU$2.88 Million | +49.05% |
| 2020-12-31 | AU$1.93 Million | -48.86% |
| 2019-12-31 | AU$3.78 Million | +80.61% |
| 2018-12-31 | AU$2.09 Million | -- |
| 2017-12-31 | AU$0.00 | -- |